BRPI0821266B8 - Derivados de arilamida triazol-substituída e seu uso e composição farmacêutica - Google Patents

Derivados de arilamida triazol-substituída e seu uso e composição farmacêutica

Info

Publication number
BRPI0821266B8
BRPI0821266B8 BRPI0821266A BRPI0821266A BRPI0821266B8 BR PI0821266 B8 BRPI0821266 B8 BR PI0821266B8 BR PI0821266 A BRPI0821266 A BR PI0821266A BR PI0821266 A BRPI0821266 A BR PI0821266A BR PI0821266 B8 BRPI0821266 B8 BR PI0821266B8
Authority
BR
Brazil
Prior art keywords
triazol
derivatives
arilamide
substituted
pharmaceutical composition
Prior art date
Application number
BRPI0821266A
Other languages
English (en)
Inventor
Chen Li
Patrick Dillon Michael
Feng Lichun
Charles Hawley Ronald
Yang Minmin
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Priority to BR122018070508A priority Critical patent/BR122018070508B8/pt
Publication of BRPI0821266A2 publication Critical patent/BRPI0821266A2/pt
Publication of BRPI0821266B1 publication Critical patent/BRPI0821266B1/pt
Publication of BRPI0821266B8 publication Critical patent/BRPI0821266B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

DERIVADOS DE ARILAMIDA TRIAZOL-SUBSTITUÍDA E SEU USO COMO ANTAGONISTAS DE RECEPTORES PURINÉRGICOS P2X3 E/OU P2X2/3. A presente invenção refere-se aos compostos da fórmula (I): I; ou um sal farmaceuticamente aceitável dos mesmos, em que, R1 é triazolila opcionalmente subs-tituída, e R2, R3, R4, R5, R6, R7 e R8 são como definidos aqui. Também revelados são métodos de usar os compostos para tratar doenças associadas com antagonistas dos receptores P2X3 e/ou P2X2/3 e métodos de fazer os compostos .
BRPI0821266A 2007-12-17 2008-12-08 Derivados de arilamida triazol-substituída e seu uso e composição farmacêutica BRPI0821266B8 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122018070508A BR122018070508B8 (pt) 2007-12-17 2008-12-08 derivados de arilamida triazol-substituída e seu uso

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US789007P 2007-12-17 2007-12-17
PCT/EP2008/066987 WO2009077366A1 (en) 2007-12-17 2008-12-08 Triazole-substituted arylamide derivatives and their use as p2x3 and /or p2x2/3 purinergic receptor antagonists

Publications (3)

Publication Number Publication Date
BRPI0821266A2 BRPI0821266A2 (pt) 2015-06-16
BRPI0821266B1 BRPI0821266B1 (pt) 2019-01-29
BRPI0821266B8 true BRPI0821266B8 (pt) 2023-02-07

Family

ID=40383852

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0821266A BRPI0821266B8 (pt) 2007-12-17 2008-12-08 Derivados de arilamida triazol-substituída e seu uso e composição farmacêutica
BR122018070508A BR122018070508B8 (pt) 2007-12-17 2008-12-08 derivados de arilamida triazol-substituída e seu uso

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR122018070508A BR122018070508B8 (pt) 2007-12-17 2008-12-08 derivados de arilamida triazol-substituída e seu uso

Country Status (12)

Country Link
US (3) US7989637B2 (pt)
EP (2) EP2225213B1 (pt)
JP (2) JP5318883B2 (pt)
KR (2) KR101284510B1 (pt)
CN (1) CN101903359B (pt)
AU (1) AU2008337660B2 (pt)
BR (2) BRPI0821266B8 (pt)
CA (1) CA2707422C (pt)
ES (2) ES2541662T3 (pt)
IL (1) IL205608A (pt)
MX (1) MX2010006230A (pt)
WO (1) WO2009077366A1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2570407B1 (en) * 2007-12-17 2014-08-13 F. Hoffmann-La Roche AG Tetrazole-substituted arylamide derivatives and their use as p2x3 and/or p2x2/3 purinergic receptor antagonists
BRPI0821266B8 (pt) * 2007-12-17 2023-02-07 Hoffmann La Roche Derivados de arilamida triazol-substituída e seu uso e composição farmacêutica
EP2262766B1 (en) 2008-02-29 2015-11-11 Evotec AG Amide compounds, compositions and uses thereof
EP2346825A2 (en) 2008-09-18 2011-07-27 Evotec AG Modulators of p2x3 receptor activity
CN102574778B (zh) 2009-06-22 2015-01-07 弗·哈夫曼-拉罗切有限公司 新的联苯基和苯基-吡啶酰胺类化合物
EP2445889B1 (en) * 2009-06-22 2016-08-10 F.Hoffmann-La Roche Ag Novel benzoxazolone -substituted arylamides
US10183937B2 (en) 2014-12-09 2019-01-22 Bayer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides
US10174016B2 (en) 2014-12-09 2019-01-08 Beyer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides
CN107207449B (zh) 2015-04-23 2020-11-10 豪夫迈·罗氏有限公司 用于治疗精神障碍的四唑衍生物
JP6831376B2 (ja) * 2015-10-06 2021-02-17 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ トリアゾール誘導体
CN108473462B (zh) 2016-02-02 2021-06-22 豪夫迈·罗氏有限公司 作为eaat3抑制剂的吡唑-吡啶衍生物
TWI679197B (zh) * 2016-05-05 2019-12-11 瑞士商伊蘭科動物健康公司 雜芳基-1,2,4-三唑及雜芳基-三唑化合物
WO2017202896A1 (en) 2016-05-27 2017-11-30 F. Hoffmann-La Roche Ag Pyrazol compounds as eaat3 inhibitors
WO2018069362A1 (en) 2016-10-14 2018-04-19 F. Hoffmann-La Roche Ag Imidazole compounds as eaat3 inhibitors
CN112888680A (zh) * 2018-10-19 2021-06-01 先正达参股股份有限公司 杀有害生物活性的唑-酰胺化合物

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL109570A0 (en) 1993-05-17 1994-08-26 Fujisawa Pharmaceutical Co Guanidine derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
US6277873B1 (en) 1999-03-25 2001-08-21 Dingwei Tim Yu Oxadiazole antifungal agents
DE60023141T2 (de) 1999-06-30 2006-06-14 Lundbeck As Valby H Selektive npy (y5) antagonisten
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EA200601591A1 (ru) 2000-05-26 2007-02-27 Айденикс (Кайман) Лимитед Применение рибонуклеозидных соединений для лечения флавивирусных и пестивирусных инфекций
JP2004501913A (ja) 2000-06-23 2004-01-22 ブリストル−マイヤーズ　スクイブ　ファーマ　カンパニー ヘテロアリール−フェニル置換Ｘａ因子阻害剤
DE10055713A1 (de) 2000-11-10 2002-05-23 Dingwei Tim Yu Neue Klasse von Antifungimitteln
WO2002057287A2 (en) 2001-01-22 2002-07-25 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
JP2005520791A (ja) 2001-11-08 2005-07-14 イーラン ファーマスーティカルズ、インコーポレイテッド Ｎ，ｎ’−置換−１，３−ジアミノ−２−ヒドロキシプロパン誘導体
AU2003208913A1 (en) 2002-01-30 2003-09-02 Entremed, Inc. Non-steroidal analogs of 2-methoxyestradiol
JP2005533777A (ja) 2002-06-17 2005-11-10 メルク　エンド　カムパニー　インコーポレーテッド Ｒｎａ抗ウイルス剤としての炭素環ヌクレオシドアナログ
JP2005533817A (ja) 2002-06-28 2005-11-10 イデニクス（ケイマン）リミテツド フラビウィルス科ウィルス感染治療用の修飾２′および３′−ヌクレオシドプロドラッグ
CA2466288A1 (en) 2002-07-18 2004-01-29 Sri International Methods of treating conditions associated with an edg-1 receptor
EP1576138B1 (en) 2002-11-15 2017-02-01 Idenix Pharmaceuticals LLC. 2'-methyl nucleosides in combination with interferon and flaviviridae mutation
TWI332507B (en) 2002-11-19 2010-11-01 Hoffmann La Roche Antiviral nucleoside derivatives
US20070043512A1 (en) 2003-03-26 2007-02-22 Michael Rolph Therapeutic and prophylactic compositions and uses therefor
US20070060584A1 (en) 2003-04-18 2007-03-15 Chakravarty Prasun K Biaryl substituted thiazoles, oxazoles and imidazoles as sodium channel blockers
WO2004099146A1 (en) 2003-05-12 2004-11-18 Pfizer Products Inc. Benzamide inhibitors of the p2x7 receptor
WO2005020885A2 (en) 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
BRPI0412849A (pt) 2003-07-25 2006-09-26 Idenix Cayman Ltd compostos, composições e usos de análogos de nucleosìdeo de purina para o tratamento de flaviviridae, incluindo hepatite c
CA2618340C (en) * 2005-08-15 2013-11-19 F.Hoffmann-La Roche Ag Piperidine and piperazine derivatives as p2x3 antagonists
EP2038264B1 (en) * 2006-06-29 2016-10-26 F.Hoffmann-La Roche Ag Tetrazole-substituted arylamides
ES2367455T3 (es) 2006-11-09 2011-11-03 F. Hoffmann-La Roche Ag Arilamidas sustituidas por tiazol u oxazol.
CA2703909A1 (en) * 2007-10-31 2009-05-07 Merck Sharp & Dohme Corp. P2x3, receptor antagonists for treatment of pain
BRPI0821266B8 (pt) * 2007-12-17 2023-02-07 Hoffmann La Roche Derivados de arilamida triazol-substituída e seu uso e composição farmacêutica

Also Published As

Publication number Publication date
JP2011506521A (ja) 2011-03-03
BRPI0821266A2 (pt) 2015-06-16
BRPI0821266B1 (pt) 2019-01-29
EP2607356B1 (en) 2015-04-29
ES2541662T3 (es) 2015-07-23
MX2010006230A (es) 2010-06-23
IL205608A0 (en) 2010-11-30
JP5318883B2 (ja) 2013-10-16
BR122018070508B8 (pt) 2021-07-27
CN101903359B (zh) 2013-05-22
AU2008337660B2 (en) 2014-02-06
KR20100083196A (ko) 2010-07-21
EP2225213A1 (en) 2010-09-08
KR101405746B1 (ko) 2014-06-10
JP2013231062A (ja) 2013-11-14
WO2009077366A1 (en) 2009-06-25
JP5697722B2 (ja) 2015-04-08
EP2607356A1 (en) 2013-06-26
IL205608A (en) 2016-03-31
CA2707422C (en) 2016-06-07
US8440708B2 (en) 2013-05-14
US20150065521A1 (en) 2015-03-05
CA2707422A1 (en) 2009-06-25
EP2225213B1 (en) 2015-04-29
ES2542245T3 (es) 2015-08-03
US20090170874A1 (en) 2009-07-02
AU2008337660A1 (en) 2009-06-25
KR101284510B1 (ko) 2013-07-23
CN101903359A (zh) 2010-12-01
US20110245271A1 (en) 2011-10-06
KR20130042002A (ko) 2013-04-25
BR122018070508B1 (pt) 2019-04-24
US7989637B2 (en) 2011-08-02

Similar Documents

Publication Publication Date Title
BRPI0821266B8 (pt) Derivados de arilamida triazol-substituída e seu uso e composição farmacêutica
BRPI0718714B8 (pt) arilamidas substituídas por tiazol e oxazol, seu uso e composição farmacêutica que as compreende
BR122019017036B8 (pt) compostos de arilamidas substituídas por tetrazol, usos dos referidos compostos e composição farmacêutica
BRPI0508461B8 (pt) diaminopirimidinas, seus usos, e composição farmacêutica
BR112012030820A8 (pt) Derivados de aminopirimidina como moduladores de lrrk2, seu uso e composição que os compreende
BR112015031903A8 (pt) composto, sal farmaceuticamente aceitável, composição farmacêutica e uso de um composto
BRPI0606644A2 (pt) derivados de 4-carboxamida tiazola
CY1111747T1 (el) 8-αζαδικυκλο[3.2.1]οκτανο ενωσεις ως ανταγωνιστες μ-οπιοειδους υποδοχεα
BR112017007662A8 (pt) Composto, composição farmacêutica e uso de um composto
BR112015028399A2 (pt) derivados 11-hidroxila de ácidos biliares e conjugados de aminoácido dos mesmos como moduladores de receptor farnesoide x
BRPI1013821A8 (pt) piridinas substituídas como antagonistas de ccr3.
BR112014011850A2 (pt) derivados de aminopirimidina como moduladores de lrrk2
DE602006006712D1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
DE602006009773D1 (de) Substituierte thiophenderivate als glucagonrezeptorantagonisten, herstellung und therapeutische anwendungen
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
EA201290394A1 (ru) Морфолинотиазолы в качестве позитивных аллостерических модуляторов альфа 7
BRPI0511778A (pt) derivados da naftalina úteis como ligantes do receptor 3 da histamina
DE602005021150D1 (de) 3-substituierte pyridinderivate als h3-antagonisten
BR112015007818A2 (pt) composto, composição farmacêutica, e, uso de um composto e de uma composição farmacêutica
BRPI0820838B8 (pt) derivados de arilamida substituídos por tetrazol, composição farmacêutica que os compreende e seu uso como antagonistas do receptor purinérgico p2x3 e/ou p2x2/3
CY1115077T1 (el) Κρυσταλλικες μορφες της ενωσης του 8-αζαδικυκλο[3.2.1]οκτανιου
BR112014012459A2 (pt) 2h-indazóis como antagonistas do receptor de ep2
ATE496918T1 (de) Als a2b-adenosinrezeptorantagonisten geeignete 5- phenyl-6-pyridin-4-yl-1,3-dihydro-2h-imidazoä4, - büpyridin-2-onderivate
ECSP10010606A (es) Derivados de quinuclidina como antagonistas de receptores muscarinicos m3
BRPI0821611A8 (pt) Derivado de 3-carboxipropil-aminotetralina e compostos relacionados como antagonistas do receptor opióide mu

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 29/01/2019, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/12/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE A RPI 2629 DE 25/05/2021, QUANTO AO ITEM (54) TITULO.